Myriad Genetics and MD Anderson Launch Strategic Partnership to Advance MRD Assays

Myriad Genetics, Inc. and The University of Texas MD Anderson Cancer Center have embarked on a five-year strategic partnership to enhance the clinical evaluation of Myriad’s next-generation molecular residual disease (MRD) assay. This collaboration aims to transform cancer diagnostics by leveraging Myriad’s expertise in oncology diagnostics and MD Anderson’s prowess in clinical research. By focusing on improving treatment strategies and patient outcomes, this alliance could significantly influence the landscape of cancer care.

The partnership between Myriad Genetics and MD Anderson represents a formidable union of cutting-edge technology and clinical expertise. MD Anderson will lead patient enrollment, sample collection, and data analysis, while Myriad will provide funding and scientific support for both retrospective and prospective studies. These studies will assess the MRD assay’s utility across various cancer types, including breast, gastrointestinal, genitourinary, and gynecological cancers.

With the aim to include Myriad’s MRD test in national guidelines, this collaboration seeks to demonstrate the assay’s capability to detect tumor-derived DNA at unprecedentedly low levels, thereby improving monitoring for relapse and identifying high-risk patients.

This strategic alliance between Myriad Genetics and MD Anderson Cancer Center marks a significant step forward in cancer diagnostics and treatment. By combining their strengths, these organizations aim to shape the future of cancer care through improved diagnostic tools and personalized treatment approaches. The outcomes of this partnership could pave the way for innovations in therapy response, recurrence monitoring, and may ultimately enhance patient care on a broader scale.

Contact James for more details.